Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin’s Byetta Records $7.5 Mil. In Sales Following June Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

Market uptake for the product could be stronger than Rx tracking numbers show due to strength in mail-order prescriptions, the company said.

You may also be interested in...



Lilly/Amylin’s Byetta Type 2 Diabetes Therapy To Launch June 1

Amylin will put 325 reps behind exenatide, in addition to a Lilly sales force. The firms will target 60,000 physicians in first six months. First-in-class gut hormone follows approval of Amylin’s diabetes therapy Symlin in March.

Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic

Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.

User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles

A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles

Topics

UsernamePublicRestriction

Register

MT003605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel